CAR T, immunotherapy bring new hope for multiple myeloma patients

(University of Pennsylvania School of Medicine) Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies. Both of these investigational approaches targeted a receptor called B-Cell Maturation Antigen (BCMA), which is highly expressed in myeloma and thus a promising target for treatment.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news